Leonard Zehr, Author at BioTuesdays

Feature

Salarius Pharmaceuticals targeting epigenetic causes of cancers

Salarius Pharmaceuticals (NASDAQ:SLRX) is poised to ride the growing epigenetic wave with a differentiated lead drug candidate, seclidemstat, in early clinical development for the treatment of Ewing sarcoma and advanced...

October 22, 2019

Feature

KemPharm sees license deal, debt restructuring as transformative events

KemPharm (NASDAQ:KMPH) hit a home run last month when it inked a transformative licensing deal of up to $493-million with an affiliate of Gurnet Point Capital, a private equity firm focused on the life science sector...

October 15, 2019

Feature

OncoSec TAVO technology aiming to reverse checkpoint inhibitor resistance

OncoSec Medical (NASDAQ:ONCS) is developing its TAVO drug candidate to enhance local delivery and uptake of DNA-based interleukin-12 (IL-12) directly into solid tumors to reverse patients’ resistance to checkpoint...

October 8, 2019

Feature

Sebastian Hadjiantoniou of Incuvers discusses accelerating cellular research

As a co-founder and CEO of closely-held Incuvers, an early-stage life sciences company developing a sophisticated incubator for cellular biologists, Sebastian Hadjiantoniou knows firsthand the rocky journey from...

October 1, 2019

Feature

INmune Bio harnessing innate immune system against cancer, neurodegenerative diseases

INmune Bio (NASDAQ:INMB) is developing new therapies that modulate the innate immune system, the body’s first line of defense against pathogens, to treat cancer and neuroinflammation that lead to neurodegenerative...

September 24, 2019

Feature

CytoDyn developing leronlimab (PRO140) as a pipeline in a drug

CytoDyn (OTCQB:CYDY), which is in the process of filing for FDA approval for leronlimab (PRO140) in treatment-experienced HIV patients, is continuing to develop its lead drug candidate in eight metastatic solid tumors...

September 17, 2019

Feature

DelMar Pharma developing VAL-083 in biomarker-driven GBM patient populations

DelMar Pharmaceuticals (NASDAQ:DMPI) is conducting two Phase 2 clinical trials with its lead drug candidate, VAL-083, a DNA-targeting agent, in three distinct biomarker-driven glioblastoma multiforme (GMB) patient...

September 10, 2019

Feature

Precipio aims to prevent misdiagnosis of blood-related cancers

Using a combination of advanced lab technologies, and a platform giving access to expert academic pathologists, Precipio (NASDAQ:PRPO) has staked out a unique position in its battle to prevent misdiagnosis of blood...

August 27, 2019

Feature

Beyond Air’s cylinder-free nitric oxide delivery system for respiratory conditions

Beyond Air (NASDAQ:XAIR), formerly AIT Therapeutics, is developing a proprietary nitric oxide (NO) generator and delivery system that uses NO generated from ambient air, rather than bulky cylinders, and delivers precise...

August 20, 2019

Feature

PharmAust readies pivotal trial in Australia to treat cancer in dogs

PharmAust (ASX:PAA) is gearing up to begin a pivotal Phase 2 study in Australia with its lead veterinary drug candidate, monepantel, for the treatment of lymphoma in canines, which if successful, could open the door to...

August 12, 2019

Author - Leonard Zehr

Salarius Pharmaceuticals targeting epigenetic causes of cancers

KemPharm sees license deal, debt restructuring as transformative events

OncoSec TAVO technology aiming to reverse checkpoint inhibitor resistance

Sebastian Hadjiantoniou of Incuvers discusses accelerating cellular research

INmune Bio harnessing innate immune system against cancer, neurodegenerative diseases

CytoDyn developing leronlimab (PRO140) as a pipeline in a drug

DelMar Pharma developing VAL-083 in biomarker-driven GBM patient populations

Precipio aims to prevent misdiagnosis of blood-related cancers

Beyond Air’s cylinder-free nitric oxide delivery system for respiratory conditions

PharmAust readies pivotal trial in Australia to treat cancer in dogs

General

More